No Data
Guoyuan Securities 2025 CSI SWS Health Care index investment strategy report: Bullish on innovation and overseas expansion, focusing on upward fundamental segmentation tracks.
The international expansion of the pharmaceutical industry remains an essential path for our country's pharmaceutical companies in the future, and companies with strong product capabilities and channel capabilities are expected to gain an advantage.
Pharmaceutical stocks have become a transitional theme at present, and the performance line may be further valued by the market.
Track the entire lifecycle of the main sector.
China Resources Pharmaceutical Group to Renew Cooperation Agreements
CHINARES PHARMA (03320.HK) has signed a strategic cooperation agreement with Banks for 2025.
On December 31, Gelonghui reported that CHINARES PHARMA (03320.HK) announced that on December 31, 2024, the company entered into a 2025 strategic cooperation agreement with CHINARES Banks and a 2025 strategic cooperation agreement with CHINARES REITs, effective from January 1, 2025, and ending on December 31, 2027.
CHINARES PHARMA (03320.HK) signed a procurement framework agreement for Information Technology Services with CHINARES Digital.
On December 30, Gelonghui reported that CHINARES PHARMA (03320.HK) announced that on December 30, 2024, the company signed a procurement framework agreement for Information Technology Services with CHINA RESOURCES Digital, whereby the group has agreed to purchase Information Technology Services from CHINA RESOURCES Digital Group, with a term starting from January 1, 2025, to December 31, 2027.
How is the quality and supply of Pharmaceuticals guaranteed? The National Healthcare Security Administration held a symposium on centralized procurement of Pharmaceuticals.
On December 26, 2024, the National Healthcare Security Administration held a symposium on centralized procurement of Pharmaceuticals, inviting representatives from the National Medical Products Administration, selected Pharmaceutical enterprises, and research Institutions to communicate and exchange views on recent societal concerns regarding quality assurance of centrally procured Pharmaceuticals and innovative development in the Industry, and to listen to opinions and suggestions.
No Data
